Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190811 | 0.83 | ALDH1A1 (0.35) | KMT2AFAAHALDH1A1LMNAPOLB | |
| SCHEMBL21403711 | 0.82 | KMT2A (0.34) | MEN1KMT2AFAAHALDH1A1 | |
| SCHEMBL21403595 | 0.82 | FAAH (0.31) | MEN1KMT2AFAAH | |
| SCHEMBL6211982 | 0.75 | MEN1 (0.36) | MEN1KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL6213862 | 0.74 | ALDH1A1 (0.35) | MEN1KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL11376421 | 0.73 | MEN1 (0.34) | MEN1KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL21403730 | 0.70 | SMN1; SMN2 (0.38) | MEN1KMT2A | |
| SCHEMBL21403728 | 0.70 | SMN1; SMN2 (0.38) | MEN1KMT2A | |
| SCHEMBL7186238 | 0.69 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1LMNAHSD17B10 | |
| SCHEMBL22183822 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155559-B2 | Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20200207772-A1 | ISOQUINOLINYLSULFONYL DERIVATIVE AND USE THEREOF | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2020-07-02 | — | — | US | disclosed |
| EP-3656772-A1 | ISOQUINOLINYLSULFONYL DERIVATIVE AND USE THEREOF | China Resources Pharmaceutical Holdings Company Limited (CN) | 2020-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207772-A1 | ISOQUINOLINYLSULFONYL DERIVATIVE AND USE THEREOF | RHOT2, ROCK2, CIT | MEN1 3877/4885KMT2A 2564/4885FAAH 3725/4885 |
| US-11155559-B2 | Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity | KCNQ2, KCNQ1, KCNH3 | MEN1 3144/4885KMT2A 2220/4885FAAH 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.